Get the Stockscreener App
1.33
3.91%
0.05
Akoya Biosciences Inc stock is traded at $1.33, with a volume of 434.33K.
It is up +3.91% in the last 24 hours and up +5.56% over the past month.
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
See More
Previous Close:
$1.28
Open:
$1.3
24h Volume:
434.33K
Relative Volume:
0.96
Market Cap:
$66.33M
Revenue:
$96.63M
Net Income/Loss:
$-63.32M
P/E Ratio:
-0.911
EPS:
-1.46
Net Cash Flow:
$-54.55M
1W Performance:
+2.31%
1M Performance:
+5.56%
6M Performance:
-45.93%
1Y Performance:
-48.45%
1-Day Range:
$1.28
$1.34
1-Week Range:
$1.195
$1.34
52-Week Range:
$0.931
$3.42
Akoya Biosciences Inc Stock (AKYA) Company Profile
Name
Akoya Biosciences Inc
Sector
Industry
Phone
855.896.8401
Address
100 CAMPUS DRIVE, MARLBOROUGH
Compare AKYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKYA
Akoya Biosciences Inc
|
1.33 | 66.33M | 96.63M | -63.32M | -54.55M | -1.46 |
|
ISRG
Intuitive Surgical Inc
|
534.19 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
169.97 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.11 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
256.21 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
219.00 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Akoya Biosciences Inc Stock (AKYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-06-24 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-06-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-21-24 | Initiated | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Feb-02-23 | Initiated | UBS | Buy |
| Nov-03-22 | Initiated | CapitalOne | Overweight |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Jun-22-22 | Initiated | BTIG Research | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| May-11-21 | Initiated | Canaccord Genuity | Buy |
| May-11-21 | Initiated | JP Morgan | Overweight |
| May-11-21 | Initiated | Morgan Stanley | Overweight |
| May-11-21 | Initiated | Piper Sandler | Overweight |
View All
Akoya Biosciences Inc Stock (AKYA) Latest News
Transcript : Akoya Biosciences, Inc.Special Call - MarketScreener
Akoya Biosciences, Inc. (NASDAQ:AKYA) Shares Sold by Jane Street Group LLC - Defense World
Deutsche Bank AG Raises Stock Holdings in Akoya Biosciences, Inc. (NASDAQ:AKYA) - Defense World
Akoya Biosciences (AKYA) Receives Price Target Cut from Morgan S - GuruFocus
Akoya Biosciences (AKYA) Receives Price Target Cut from Morgan Stanley | AKYA Stock News - GuruFocus
Northern Trust Corp Buys 39,799 Shares of Akoya Biosciences, Inc. (NASDAQ:AKYA) - Defense World
Spatial proteomics Market Worth Observing Growth: Bruker, Akoya Biosciences, PerkinElmer - newstrail.com
Spatiotemporal Omics Market Research Report 2025-2035, Competitive Analysis of Prominent Players10X Genomics, Akoya Biosciences, Bruker, Curio Bioscience, IonPath, MGI, and RareCyteResearchAndMarkets.com - FinancialContent
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Average Recommendation of “Hold” from Brokerages - Defense World
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - Benzinga
Quanterix Merger Drama: 6.9% Holder Fights Board as Rival $1.40 Cash Offer Threatens Deal - Stock Titan
Akoya surges as unsolicited buyout offer risks Quanterix merger - MSN
Akoya Biosciences (AKYA) Soars on New Acquisition Proposal - GuruFocus
An undisclosed buyer agreed to acquire Akoya Biosciences, Inc.. - marketscreener.com
Akoya Biosciences Receives Unsolicited Buyout Offer From Third Party - marketscreener.com
Akoya Biosciences considering unsolicited buyout amidst merger proceedings - Worcester Business Journal
Akoya stock surges as new buyout bid risks Quanterix deal (AKYA) - Seeking Alpha
Akoya Biosciences reviews unsolicited acquisition proposal By Investing.com - Investing.com Nigeria
Akoya Biosciences reviews unsolicited acquisition proposal - Investing.com India
Akoya Biosciences IncOn May 20, Receives Unsolicited Acquisition Proposal At $1.40 Per Share From A Third Party- SEC Filing - marketscreener.com
Akoya Biosciences (NASDAQ:AKYA) Given New $1.08 Price Target at Canaccord Genuity Group - Defense World
Akoya Biosciences Reports Q1 2025 Financial Results - TipRanks
Akoya Biosciences (AKYA) Target Price Reduced by Canaccord | AKY - GuruFocus
Akoya Biosciences (AKYA): Analyst Lowers Price Target | AKYA Sto - GuruFocus
Akoya Biosciences (AKYA): Analyst Lowers Price Target | AKYA Stock News - GuruFocus
Akoya Biosciences (AKYA) Target Price Reduced by Canaccord | AKYA Stock News - GuruFocus
Akoya Biosciences (AKYA) Faces Uncertainty Amid Merger and Marke - GuruFocus
Akoya Biosciences, Inc. SEC 10-Q Report - TradingView
Akoya: Q1 Earnings Snapshot - The Washington Post
Akoya Biosciences earnings missed by $0.11, revenue fell short of estimates - Investing.com Canada
Akoya Biosciences (AKYA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Akoya Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Akoya Biosciences Inc Reports Q1 2025 Earnings: EPS of -$0.18 Be - GuruFocus
Akoya Biosciences Reports First Quarter 2025 Financial Results - The Manila Times
Akoya Biosciences (AKYA) Projected to Post Quarterly Earnings on Monday - Defense World
AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc.AKYA - Business Wire
Akoya Biosciences, Inc. (NASDAQ:AKYA) Shares Acquired by JPMorgan Chase & Co. - Defense World
Quanterix and Akoya Biosciences Announce Amended Merger Agreement - ADVFN
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Average Recommendation of “Hold” by Analysts - Defense World
Canaccord Genuity Group Has Lowered Expectations for Akoya Biosciences (NASDAQ:AKYA) Stock Price - Defense World
AKYA Merger Faces Backlash Amid Shareholder Discontent | AKYA St - GuruFocus
Quanterix Acquisition of Akoya Biosciences (AKYA) Faces Challenges | AKYA Stock News - GuruFocus
Kent Lake Issues Statement on Quanterix?s Amendment to Merger with Akoya Biosciences - marketscreener.com
Quanterix, Akoya Biosciences Amend Merger Deal - marketscreener.com
Akoya stock falls on amended Quanterix merger deal (AKYA) - Seeking Alpha
Quanterix Revises Merger Terms with Akoya Biosciences - TipRanks
Merger Amendment: Changes to Quanterix and Akoya Biosciences (AK - GuruFocus
Quanterix And Akoya Biosciences Announce Amended Merger Agreement - marketscreener.com
Canaccord Adjusts Price Target for Akoya Biosciences (AKYA) | AK - GuruFocus
Akoya Biosciences introduces new assay for breast cancer ADC development By Investing.com - Investing.com South Africa
Akoya Biosciences Inc Stock (AKYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.43%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):